Current Use of Nephelometric Quantification of Serum Free Light Chains (FLCs) in the Management of Plasma Cell Dyscrasias, and the Potential Benefits of Point-Of-Care Testing.

Loading...
Thumbnail Image
Authors
Veale, Dave
McCulloch, Rory
O'Connor, John
Parfitt, Ceri
Cudmore, Adrian
Kerr, Paul
Journal
Type
Meetings and Proceedings
Publisher
DOI
Rights
Quantitative nephelometric assays detecting polyclonal sheep anti-sera and serum FLCs (e.g. FreeliteĀ®) are the gold standard method for monitoring FLC secretion from myeloma cells, but are only available in central laboratories. The frequent delay between venepuncture and assay results can affect diagnosis, treatment decisions and patient communication. Second generation point-of-care assays have been developed using monoclonal antibodies to FLCs, producing results in 10 minutes (e.g. SeraliteĀ®). This study investigates potential impact on care of patients with plasma cell dyscrasias.
Citation
Publisher URL
Note